HIT-HARD Trial Protocol Tests Short-Course High-Dose Antibiotics

The HIT-HARD trial protocol describes a phase III multicenter study designed to evaluate whether a short-course, high-dose beta-lactam antibiotic strategy is non-inferior to conventional dosing and duration in critically ill patients with severe infections. Published in BMC Infectious Diseases, the protocol outlines a prospective, cluster-randomized, cross-over, non-inferiority trial intended to address the frequent underdosing of beta-lactam antibiotics in this patient population. The study aims to determine if adequately dosed, shorter treatment durations are sufficient, potentially reducing the development of antimicrobial resistance while maintaining clinical efficacy. This approach is proposed as part of an intensive care unit stewardship program to guide evidence-based antibiotic policy.

The trial, identified by the EU reference number 2024-514730-21-00, will be conducted in 14 hospitals, with seven located in Belgium and seven in the Netherlands. The study design involves enrolling 1,282 patients who present with organ dysfunction due to common infections. Eligible infections include community-acquired pneumonia, hospital-acquired pneumonia, ventilator-associated pneumonia, intra-abdominal infection, or bloodstream infection. The protocol specifies that patients treated with ceftriaxone, cefuroxime, cefotaxime, piperacillin–tazobactam, or meropenem can be included in the study.

Patients are excluded if they have received prior study-antimicrobial therapy for more than 12 hours for the current infection.

Participants in the HIT-HARD trial are allocated to one of two strategies. The HIT-HARD strategy involves a high-dose regimen, defined as approximately 150 to 200 percent of standard dosing, administered for a short course of 3 to 5 days, which corresponds to a treatment duration of 72 to 120 hours. In contrast, the CONTROL strategy utilizes a conventional dosing regimen for a longer duration of 6 to 9 days, equivalent to 144 to 216 hours. This comparison directly tests the hypothesis that increasing the dose while simultaneously shortening the treatment period can achieve similar outcomes to the standard, lower-dose, longer-duration approach.

Secondary endpoints are extensive and include mortality at other time points, recurrence of infection, development of antimicrobial resistance, toxicity, antimicrobial exposure, and clinical cure. The study also assesses resource utilization, health-related quality of life, and cost-effectiveness.

Statistical analysis for the trial is designed to assess non-inferiority using a pre-specified 7 percent margin. This assessment will be conducted by estimating the risk difference between the HIT-HARD and CONTROL groups.

The protocol notes that the study is registered prospectively, with a registration date of December 5, 2024. The protocol version is 3.0, dated June 1, 2026. The article is published as an open access study protocol, providing full access to the research design and methods. The authors, including L. H. Roest, M. Demaria, and J. J. De Waele, represent the HIT-HARD investigators.

If the trial determines that the short-course, high-dose approach is non-inferior to conventional regimens, the findings could directly inform antibiotic policy. This would support an evidence-based approach to safely shortening antimicrobial therapy, which is a key component of ICU stewardship programs. However, the trial is currently in the protocol stage, and no efficacy results are available from this publication. The study aims to generate the necessary evidence to guide clinical practice in the management of severe infections in critically ill patients.

Subject of Research: Protocol for a phase III trial comparing short-course high-dose beta-lactam therapy to conventional dosing in critically ill patients

Article Title: Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial

Article References: Roest, L. H., Demaria, M., Vermeiren, D., van den Berg, C. H. S. B., Boelens, J., De Bus, L., Brüggemann, R. J. M., Hites, M., Kievit, W., ten Oever, J., De Schryver, N., Spriet, I., Teerenstra, S., Jager, N. G. L., Schouten, J. A., De Waele, J. J., & On behalf of the HIT-HARD investigators (2026). Short-course, high-dose beta-lactam therapy versus conventional dose and duration in critically ill patients: the HIT-HARD trial protocol for a phase III multicenter, cluster randomized, cross-over, non-inferiority trial. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14707-3

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14707-3

Keywords: HIT-HARD trial, beta-lactam antibiotics, critical care, antibiotic stewardship, non-inferiority trial, cluster-randomized design, severe infections, antimicrobial resistance, high-dose therapy, short-course treatment, BMC Infectious Diseases, phase III trial, 90-day mortality, ICU stewardship, ceftriaxone, piperacillin-tazobactam, meropenem, clinical trial protocol, organ dysfunction, community-acquired pneumonia